Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib

Abstract Background First‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sometimes causes lung injury, thereby affecting survival. Although pre‐existing interstitial lung abnormal shadow (pre‐ILS) increases the risk of lung injury by EGFR‐TKIs, its impact on osimert...

Full description

Bibliographic Details
Main Authors: Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, Shinya Tamaki, Masanori Nakanishi, Shunsuke Teraoka, Hiroaki Akamatsu
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Cancer Medicine
Subjects:
epidermal growth factor receptor
interstitial lung abnormalities
lung injury
non‐small cell lung cancer
Online Access:https://doi.org/10.1002/cam4.4750

Internet

https://doi.org/10.1002/cam4.4750

Similar Items